Trial Profile
University of Arkansas (UARK# 2017-03): A Single-Arm, Open-label Study of Anti-SLAMF7 mAb Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma (Total Therapy 8)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Elotuzumab (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms UARK# 2017-03
- 25 Jan 2019 Planned End Date changed from 1 Jul 2028 to 24 Jan 2019.
- 25 Jan 2019 Planned primary completion date changed from 1 Jun 2020 to 24 Jan 2019.
- 25 Jan 2019 Status has been changed to withdrawn prior to enrolment.